Structural basis for agonism and antagonism of hepatocyte growth factor
- 12 July 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (30), 13264-13269
- https://doi.org/10.1073/pnas.1005183107
Abstract
Hepatocyte growth factor (HGF) is an activating ligand of the Met receptor tyrosine kinase, whose activity is essential for normal tissue development and organ regeneration but abnormal activation of Met has been implicated in growth, invasion, and metastasis of many types of solid tumors. HGF has two natural splice variants, NK1 and NK2, which contain the N-terminal domain (N) and the first kringle (K1) or the first two kringle domains of HGF. NK1, which is a Met agonist, forms a head-to-tail dimer complex in crystal structures and mutations in the NK1 dimer interface convert NK1 to a Met antagonist. In contrast, NK2 is a Met antagonist, capable of inhibiting HGF’s activity in cell proliferation without clear mechanism. Here we report the crystal structure of NK2, which forms a “closed” monomeric conformation through interdomain interactions between the N- domain and the second kringle domain (K2). Mutations that were designed to open up the NK2 closed conformation by disrupting the N/K2 interface convert NK2 from a Met antagonist to an agonist. Remarkably, this mutated NK2 agonist can be converted back to an antagonist by a mutation that disrupts the NK1/NK1 dimer interface. These results reveal the molecular determinants that regulate the agonist/antagonist properties of HGF NK2 and provide critical insights into the dimerization mechanism that regulates the Met receptor activation by HGF.This publication has 37 references indexed in Scilit:
- Alternative Proteolytic Processing of Hepatocyte Growth Factor during Wound RepairThe American Journal of Pathology, 2009
- Engineering the NK1 Fragment of Hepatocyte Growth Factor/Scatter Factor as a MET Receptor AntagonistJournal of Molecular Biology, 2008
- A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonistProceedings of the National Academy of Sciences of the United States of America, 2007
- Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonistProceedings of the National Academy of Sciences of the United States of America, 2007
- Insights into the Structure/Function of Hepatocyte Growth Factor/Scatter Factor from Studies with Individual DomainsJournal of Molecular Biology, 2007
- Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like AntagonistsPublished by Elsevier BV ,2006
- Mechanisms and significance of bifunctional NK4 in cancer treatmentBiochemical and Biophysical Research Communications, 2005
- The Interactions of Hepatocyte Growth Factor/Scatter Factor and Its NK1 and NK2 Variants with Glycosaminoglycans Using a Modified Gel Mobility Shift AssayPublished by Elsevier BV ,2004
- Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor β-Chain in Met Binding and SignalingPublished by Elsevier BV ,2004
- Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates MetastasisMolecular and Cellular Biology, 2000